Teva Outlines Aggressive R&D Strategy with $7 Billion in Innovative Medicine Revenue by 2030

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) on Wednesday said it targets $6 billion to $7 billion in innovative medicine revenue by 2030.

President and CEO Richard Francis outlined a comprehensive strategy aiming to launch one novel treatment annually over the next five years.

The presentation emphasizes the company’s refined research and development model, which relies on data-driven capital allocation and accelerated clinical timelines.

Teva’s late-stage pipeline currently holds a combined peak sales potential exceeding $10 billion, pending regulatory approvals.

The company recently accelerated development schedules for WELTRUZA, moving directly from Phase 1 to Phase 3, and advanced ecopipam to FDA priority review.

Advancing Clinical Candidates

Teva highlighted multiple early-stage pipeline assets to sustain growth beyond 2030.

The Anti-IL-15 program for celiac disease achieved its primary Phase 2a endpoint, with a Phase 2b trial planned for the second half of 2027.

Furthermore, the TEV-’408 asset is moving seamlessly into Phase 2/3 trials for vitiligo and will undergo evaluation for alopecia.

The company is also progressing its anti-PD-1/IL-2 asset, ATTENUKINE, in Phase 1 trials for advanced cancer, while utilizing in-house capabilities to develop precision antibodies for asthma and inflammatory bowel disease.

Execution And Financial Stabilization

Since initiating its Pivot to Growth strategy in 2023, Teva successfully doubled its innovative medicine revenue.

Key products including AUSTEDO, AJOVY, and UZEDY are projected to grow roughly 125% by the close of 2026.

The company recently launched WELTRUZA, pushing innovative medicines to over 20% of total revenue.

Simultaneously, the generics segment stabilized, biosimilar revenue is forecast to double between 2024 and 2026, and the company generated over $6 billion in free cash flow from 2023 to 2025.

Robust 2030 Financial Outlook

Regaining an investment-grade credit rating in 2026 provided Teva with a solid financial foundation to fund pipeline expansions and commercial launches.

Looking toward 2030, the pharmaceutical company targets innovative gross margins above 75%, mid-single-digit total revenue growth, and more than $3.5 billion in annual free cash flow.

Additionally, management established a clear path to lower its net debt leverage to 2.0x by late 2027.

TEVA Price Action: Teva Pharmaceutical Indus shares were up 0.47% at $42.60 at the time of publication on Wednesday. The stock is trading near its 52-week high of $43.34, according to Benzinga Pro data.

Photo: Shutterstock